Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder

Carlberg, Laura; Scheibelreiter, Janine; Hassler, Melanie R.; Schloegelhofer, Monika; Schmoeger, Michaela; Ludwig, Birgit; Kasper, Siegfried; Aschauer, Harald; Egger, Gerda; Schosser, Alexandra

doi:10.1016/j.jad.2014.07.022

Cited by 75 publications

(64 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased DNA methylation at Bdnf gene promoter was observed in DNA from peripheral blood mononuclear cells of patients affected with major Page 10 of 20 A c c e p t e d M a n u s c r i p t 9 depression as compared to control subjects [34,35]. However, lower methylation levels in saliva DNA were associated with symptoms of depression in Japanese workers [36].…”

Section: Discussionmentioning

confidence: 99%

Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients

Carboni

Lattanzio

Candeletti

et al. 2015

Neuroscience Letters

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients

Carboni

Lattanzio

Candeletti

et al. 2015

Neuroscience Letters

View full text Add to dashboard Cite

“…The CpG island of the BDNF gene upstream of exon I was found as a possible diagnostic biomarker of MDD (Fuchikami et al 2011), and higher methylation status of the BDNF promoter was associated with MDD (D 'Addario et al 2013;Carlberg et al 2014;Dell'Osso et al 2014;Januar et al 2015) and post-stroke depression ).…”

Section: Gene Methylationmentioning

confidence: 99%

“…The effect of antidepressant drugs on BDNF promoter methylation levels is still scarcely investigated and available data suggested a possible higher methylation status in treated versus untreated patients (Carlberg et al 2014), but an enhanced reduction in suicidal ideation after treatment in subjects with low methylation levels (Kang et al 2013a). Methylation levels may also be reduced in patients receiving combination treatments of antidepressants plus mood stabilisers compared to patients on antidepressant drugs alone (D'Addario et al 2013).…”

Section: Gene Methylationmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under-or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in anti-depressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-a receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

show abstract

“…This subject has several implications, since cross-tissue epigenetic changes may constitute the very biological basis of some peripheral blood biomarkers of depression [5,28,35].…”

Section: Discussionmentioning

confidence: 99%

Further Evidence ofDepdc7Dna Hypomethylation in Depression: a Study in Adult Twins

et al. 2015

View full text Add to dashboard Cite

Late and early stressful factors have widely been recognized to play a role in the aetiology of depression. Recent research indicates that such adverse environmental stimuli may alter gene expression in humans via epigenetic modifications. While epigenetic changes such as DNA methylation are likely involved in these processes, it is still unknown what specific genomic loci may be hyper- or hypo-methylated in depression. The association between depressive symptoms during the last 30 days (Brief Symptom Inventory [BSI]) and peripheral-blood DNA methylation levels at genomic loci previously reported as epigenetically altered in saliva and brain of depressive patients was evaluated in a community sample of 34 adult Caucasian MZ twins (17 pairs). Intrapair DNA methylation differences in an intron of DEPDC7 (chr11:33040743) were associated with intrapair differences in current depressive symptoms. Accordingly, a site-specific 10% DNA hypomethylation in a co-twin would correlate with a current depressive symptom score around 3.1 BSI points above the score of his/her less-depressed co-twin. These findings indicate that DEPDC7 hypomethylation in peripheral blood DNA may be associated with recent depressive symptomatology, in line with previous results.

show abstract

Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder

Cited by 75 publications

References 40 publications

Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients

Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Further Evidence ofDepdc7Dna Hypomethylation in Depression: a Study in Adult Twins

Contact Info

Product

Resources

About